The homodimeric structure of human S100A16 in the apo state has been obtained both in the solid state and in solution, resulting in good agreement between the structures with the exception of two loop regions. The homodimeric solution structure of human S100A16 was also calculated in the calcium(II)-bound form. Differently from most S100 proteins, the conformational rearrangement upon calcium binding is minor. This characteristic is likely to be related to the weak binding affinity of the protein for the calcium(II) ions. In turn, this is ascribed to the lack of the glutamate residue at the end of the S100-specific N-domain binding site, which in most S100 proteins provides two important side chain oxygen atoms as calcium(II) ligands. Furthermore, the presence of hydrophobic interactions stronger than for other S100 proteins, present in the closed form of S100A16 between the third and fourth helices, likely make the closed structure of the second EF-hand particularly stable, so even upon calcium(II) binding such a conformation is not disrupted.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00775-010-0721-3DOI Listing

Publication Analysis

Top Keywords

human s100a16
12
s100 proteins
12
structure human
8
structural characterization
4
characterization human
4
s100a16
4
s100a16 low-affinity
4
low-affinity calcium
4
calcium binder
4
binder homodimeric
4

Similar Publications

Accumulating evidence supports the notion that S100A16 exhibits differential expression in many human cancers, affecting cellular functions associated with tumorigenesis through various signaling pathways. While extensive research has been conducted on S100A16 in specific cancer types, a comprehensive evaluation of its role across diverse cancers remains lacking. To explore the prognostic significance, drug sensitivity, and immunomodulatory roles of S100A16, a thorough analysis was conducted at a pan-cancer level using multiple databases.

View Article and Find Full Text PDF
Article Synopsis
  • Lung adenocarcinoma (LUAD) is linked to high mortality rates, and the protein S100A16 is suggested to have prognostic importance in this cancer, although its exact mechanism is unclear.
  • The study analyzed S100A16 expression in LUAD tissues and cells, revealing that higher levels of S100A16 correlate with poorer patient outcomes and that reducing S100A16 decreases cell growth, migration, invasion, and angiogenesis.
  • It was found that S100A16 interacts with the MOV10 protein, stabilizes ITGA3 mRNA, and affects ECM-receptor interactions, ultimately enhancing the aggressive characteristics of LUAD.
View Article and Find Full Text PDF

Integrating machine learning and single-cell analysis to uncover lung adenocarcinoma progression and prognostic biomarkers.

J Cell Mol Med

July 2024

Department of Lung Cancer, Tianjin Lung Cancer Center, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

The progression of lung adenocarcinoma (LUAD) from atypical adenomatous hyperplasia (AAH) to invasive adenocarcinoma (IAC) involves a complex evolution of tumour cell clusters, the mechanisms of which remain largely unknown. By integrating single-cell datasets and using inferCNV, we identified and analysed tumour cell clusters to explore their heterogeneity and changes in abundance throughout LUAD progression. We applied gene set variation analysis (GSVA), pseudotime analysis, scMetabolism, and Cytotrace scores to study biological functions, metabolic profiles and stemness traits.

View Article and Find Full Text PDF

Resistance to gemcitabine is mediated by the circ_0036627/miR-145/S100A16 axis in pancreatic cancer.

J Cell Mol Med

June 2024

Department of Biliary-Pancreatic Surgery, Affiliated Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

Article Synopsis
  • Gemcitabine resistance is a major challenge in treating pancreatic cancer (PC), with circular RNAs (circRNAs) playing important roles in tumor progression and drug resistance.
  • This study focuses on circ_0036627, which is found to be highly expressed in PC tissues and associated with worse outcomes in patients; its overexpression promotes cell proliferation, migration, invasion, and resistance to gemcitabine.
  • The research reveals that circ_0036627 acts by sponging microRNA-145 to increase S100A16 levels, suggesting a critical circ_0036627/miR-145/S100A16 pathway that could serve as a potential target for new PC therapies.
View Article and Find Full Text PDF

Potential drug targets for tumors identified through Mendelian randomization analysis.

Sci Rep

May 2024

Department of Pathology, Xinxiang Key Laboratory of Precision Medicine, The First Affiliated Hospital of Xinxiang Medical University, Jiankang Road No.88, Xinxiang, 453100, China.

According to the latest cancer research data, there are a significant number of new cancer cases and a substantial mortality rate each year. Although a substantial number of clinical patients are treated with existing cancer drugs each year, the efficacy is unsatisfactory. The incidence is still high and the effectiveness of most cancer drugs remains unsatisfactory.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!